Metabolic · Generation 3 · Frontier

RetaLeanRetatrutide

Triple GLP-1/GIP/glucagon agonist · phase 3 complete · up to 28.3% weight loss at 80 weeks (30.3% at 2 years)

The ReferenceBenefits, protocols and preparationOpen the reference →
Purity
≥99%
Format
10mg · 20mg
Trend 24m
+512%
Phase
FDA III
Phase 3 complete · BLA announced for 2027What this means ›
🇺🇸 United States · Phase 3 complete

Phase 3 trials have read out; the approval application is not yet filed in United States. Eli Lilly's TRIUMPH programme has now read out in full. TRIUMPH-1 (pivotal, 2,339 adults): up to 28.3% body weight, the highest figure recorded for a single obesity medicine. TRIUMPH-4 (with knee osteoarthritis): 28.7% at 68 weeks. On 23 July 2026 the last two reported: TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes) 12.7% to 20.8% at 80 weeks versus 4.0% on placebo, with A1C down up to 1.6 points; and TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease) 21.6% to 22.6% at 80 weeks versus 3.2% on placebo, plus improvements in lipids, blood pressure, hsCRP and waist. Lilly announced it will file for approval in the first quarter of 2027. In June 2026 the TRIUMPH-1 baskets were presented: knee osteoarthritis pain −73.1% (4.3 points; −75.8% in TRIUMPH-4, the dedicated trial) and moderate-to-severe sleep apnea −60.6% (36 fewer events per hour); TRIUMPH-1 was published in NEJM (June 2026, ADA) and on 29 September 2026 TRIUMPH-2 was published in full in The Lancet (EASD 2026). In type 2 diabetes without obesity, TRANSCEND-T2D-1 read out in March 2026 and was published in full in The Lancet in June 2026. The dedicated cardiovascular trial (TRIUMPH-Outcomes) reports around 2028–2029. What the class has shown and is still unmeasured here: heart and kidney (TRIUMPH-Outcomes, primary completion February 2029) and liver inflammation. Next step: filing the approval application.

Phase 3 is complete and the FDA filing is expected for 2027 or 2028: until then, retatrutide is an investigational compound, and Lilly, on its own page (September 2026), says it distributes it only inside its trials. What CAN be checked in a vial, by independent analysis (HPLC and mass spectrometry), is its identity, purity and content: that is why every lot of ours carries a verifiable certificate of analysis. Clinical approval comes from the agency; ours is research-use-only material.

Source: Eli Lilly · TRIUMPH-1 (may 2026; canastas jun 2026; NEJM jun 2026), TRIUMPH-2 y TRIUMPH-3 (23 jul 2026; TRIUMPH-2 en The Lancet 29 sep 2026), TRIUMPH-4 (11 dic 2025), TRANSCEND-T2D-1 (mar y jun 2026, The Lancet) · FAQ de Lilly «What to know about retatrutide» (sep 2026) · TRIUMPH-Outcomes NCT06383390

For research use only (RUO) Ships from Quito · EC 1-3 days · LATAM 4-10 Arrives damaged? We replace it free COA per batch
CAS · 2381089-83-2 MW · 4731 Da Stock · Available
How it works

4 mechanisms. One peptide.

What this peptide does at the cellular level, in plain words.

GLP-1 activation

First of the three receptors. Satiety and glycemic control.

GIP activation

Second receptor. Synergizes with GLP-1 to amplify metabolic effect.

Glucagon activation

Third receptor. Increases energy expenditure and fat oxidation.

Triple agonist

Phase 3 (TRIUMPH-1, 2026): up to 28.3% of body weight at 80 weeks and 30.3% at 2 years. Category record.

Why combine it

Lose weight & curb appetite

See all combinations in the Consultation →
The compound

Technical description.

Retatrutide (also known as LY3437943) is the first triple agonist peptide in the GLP-1 class, targeting GLP-1, GIP and glucagon receptors with a single molecule. It completed its first phase 3 trials with Eli Lilly (TRIUMPH program, 2025-2026) and is not yet approved: it is the frontier of metabolic peptide research.

SuperBio Labs Retatrutide is provided as lyophilized powder, ≥99% pure by HPLC, with full LC-MS sequence confirmation. Each batch is supplied with an independent Certificate of Analysis covering purity, peptide content (98–102%), endotoxin levels (<1.0 EU/mg), and residual solvents.

The triple agonist mechanism sets retatrutide apart from single (semaglutide) and dual (tirzepatide) agonists: the glucagon receptor raises energy expenditure and fat burning, while GLP-1 + GIP reduce appetite and improve insulin sensitivity. In phase 3 it reached up to 28.3% weight reduction at 80 weeks on 12 mg (TRIUMPH-1, 2,339 adults; 30.3% at 104 weeks in severe obesity) and 28.7% at 68 weeks in the osteoarthritis trial (TRIUMPH-4). In the osteoarthritis trial (TRIUMPH-4) knee pain fell 75.8% (4.5 WOMAC points; more than 1 in 8 became pain-free) and in the TRIUMPH-1 knee basket, 73.1%; in moderate-to-severe sleep apnea breathing pauses per hour fell 60.6% (36 fewer events per hour). With type 2 diabetes it lost up to 20.8% and cut A1C by 1.5 points (TRIUMPH-2); with severe obesity and cardiovascular disease, 22.6%, with triglycerides −37% and systolic blood pressure −9 mmHg (TRIUMPH-3). Major cardiovascular events were fewer than with placebo (ratio 0.82) without reaching significance: the dedicated cardiovascular trial (TRIUMPH-Outcomes) reports around 2028–2029. Lilly will file for approval in the first quarter of 2027. What the GLP-1 class has already shown and retatrutide has not yet measured: heart and kidney outcomes (TRIUMPH-Outcomes, around 2029), biopsy-proven liver inflammation (phase 3 announced), psoriasis and alcohol (no trial). The rest — weight, knee, apnea, glucose, lipids, blood pressure and inflammation — it already holds in its own right.

Informed professional research use only.

Your complete kit, ready to apply.

We don't just hand you the vial. Every Retatrutide purchase includes everything you need to apply it safely, with a clear protocol and our team available 24/7.

Complete Retatrutide kit · 8 components

Retatrutide vial

Lyophilized · HPLC purity ≥99% · Batch with COA

BAC

Bacteriostatic water 30ml

Sterile diluent · 0.9% benzyl alcohol

3ml

1 extraction syringe 3ml

21G needle · For peptide reconstitution

5–10 insulin syringes (29G)

10mg → 5 · 20mg → 10 · 1×/week

70%

6–11 alcohol wipes 70%

10mg → 6 · 20mg → 11 · 1 per application + 1 to reconstitute

Your protocol and product sheet, in the app

Free app · Week-by-week protocol, product sheet and usage guide

Visual step-by-step guide

8 steps · From opening the kit to application

SuperBio OS · Support

App · Tracking · Human team 24/7

About supplies: the quantity of syringes and wipes adjusts automatically based on the presentation you choose. For extended cycles (BPC-157, GHK-Cu and similar) we cap supplies at 30 days — beyond that, 29G insulin syringes and 70% alcohol wipes are pharmacy items available without prescription in any city.

Before you buy · from any store

How to choose where to buy peptides.

01
Per-batch, verifiable COA The certificate exists and can be checked — not "available on request".
→
02
HPLC purity + LC-MS identity How much is in the vial, and that it is the right peptide.
→
03
Endotoxins tested LAL test within range — not just purity.
→
04
2-8°C cold chain Documented end to end, not promised.
→
05
Traceability and support Lot number on the vial and someone who answers after.

This product meets all five — your batch COA ships with the kit.

Recommended application protocol.

The official protocol included in the kit. If you have pre-existing medical conditions, consult a professional before starting.

Reconstitution
1 ml (10 mg) · 2 ml (20 mg) of bacteriostatic water → 10 mg/ml
Starting dose
1.5 mg
Target dose
1.5 → 3 mg
Frequency
1×/week
Cycle duration
16 weeks
Application site
Subcutaneous · abdomen / thigh / arm
Storage (reconstituted)
60 days refrigerated (2–8°C)

Recommended titration

Wk 1–4: 1.5 mg → Wk 5–8: 2 mg → Wk 9–12: 2.5 mg → Wk 13–16: 3 mg

Note

Triple agonist GLP-1 + GIP + glucagon. Frontier molecule.

When to use Retatrutide.

High weight goal

The largest reduction recorded in its class (TRIUMPH-1: up to 28.3% at 80 weeks and 30.3% at 2 years).

Fatty liver

Liver fat −82% in the phase 2 substudy.

Cardiometabolic risk

Waist, triglycerides, blood pressure and glucose together (TRIUMPH-3).

Plateau on another GLP-1

Glucagon adds energy expenditure · switch one for the other, never both.

Knee pain with excess weight

TRIUMPH-4: knee pain −75.8% and more than 1 in 8 pain-free, together with −28.7% weight.

Recomposition

With strength training, high protein, MOTS-c and tesamorelin · see Recomposition · Reta.

Sleep apnea

Moderate-to-severe apnea: 60.6% fewer pauses per hour (36 fewer events) in phase 3.

Honest side effects.

The GLP-1 profile, stronger, plus one effect of its own. In TRIUMPH-1 (2,339 adults; 4, 9 and 12 mg): nausea 29–42%, diarrhea 25–34%, constipation 24–26%, vomiting 11–25% (placebo 5–15%). Mostly mild or moderate and concentrated during dose escalation.

Specific to retatrutide: dysesthesia (tingling or sensitive skin) in 5% at 4 mg, 12% at 9 mg and 12.5% at 12 mg in TRIUMPH-1 (up to 20.9% at 12 mg in TRIUMPH-4), almost always mild and usually resolving without stopping treatment. In phase 2, heart rate rose by a few beats in the first weeks. Discontinuation due to adverse events was 4% at 4 mg, 7% at 9 mg and 11% at 12 mg (placebo 5%), which is why we titrate slowly. In TRIUMPH-2 and TRIUMPH-3 dysesthesia was 4.5–7.3% and 6.4% versus 0.7–1.3% on placebo. Two class notices: if you are having surgery or an endoscopy under sedation, say you use a GLP-1 (slow gastric emptying; FDA label, Nov 2024); and seek care at once for sudden vision loss (NAION, "very rare" with semaglutide per the EMA, Jun 2025). If you vomit or have diarrhea, hydrate: dehydration can harm the kidney. Do not use with prior pancreatitis, medullary thyroid cancer or MEN2, pregnancy, or together with another GLP-1.

Technical specifications

CAS number2381089-83-2
Molecular weight4731 Da
Purity (HPLC)≥99%
FormatLyophilized powder
Quantity10 / 20 mg per vial
Endotoxins<1.0 EU/mg
Storage−20 °C, protected from light
UseUse under professional judgment

Also in Metabolic Series